LEAP THERAPEUTICS INC (LPTX) Stock Price & Overview
NASDAQ:LPTX • US52187K2006
Current stock price
The current stock price of LPTX is 2.05 USD. Today LPTX is up by 368.57%. In the past month the price increased by 228.53%. In the past year, price decreased by -25.18%.
LPTX Key Statistics
- Market Cap
- 116.132M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.22
- Dividend Yield
- N/A
LPTX Stock Performance
LPTX Stock Chart
LPTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LPTX. When comparing the yearly performance of all stocks, LPTX is one of the better performing stocks in the market, outperforming 99.51% of all stocks.
LPTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LPTX. The financial health of LPTX is average, but there are quite some concerns on its profitability.
LPTX Earnings
LPTX Forecast & Estimates
LPTX Groups
Sector & Classification
LPTX Financial Highlights
Over the last trailing twelve months LPTX reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS increased by 36.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -327.74% | ||
| ROE | -1148.94% | ||
| Debt/Equity | 0 |
LPTX Ownership
LPTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.97 | 391.561B | ||
| AMGN | AMGEN INC | 15.81 | 197.434B | ||
| GILD | GILEAD SCIENCES INC | 16.34 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.04 | 118.403B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.24 | 80.021B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.61 | 42.294B | ||
| INSM | INSMED INC | N/A | 31.169B | ||
| NTRA | NATERA INC | N/A | 28.017B | ||
| BIIB | BIOGEN INC | 11.42 | 26.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.94 | 23.418B | ||
| MRNA | MODERNA INC | N/A | 21.054B | ||
| EXAS | EXACT SCIENCES CORP | 341.87 | 19.824B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.619B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LPTX
Company Profile
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The firm is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The firm also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Company Info
IPO: 2017-01-24
LEAP THERAPEUTICS INC
47 Thorndike St, Suite B1-1
Cambridge MASSACHUSETTS 02141 US
CEO: Douglas E. Onsi
Employees: 52
Phone: 16177140360
LEAP THERAPEUTICS INC / LPTX FAQ
Can you describe the business of LEAP THERAPEUTICS INC?
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The firm is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The firm also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Can you provide the latest stock price for LEAP THERAPEUTICS INC?
The current stock price of LPTX is 2.05 USD. The price increased by 368.57% in the last trading session.
Does LPTX stock pay dividends?
LPTX does not pay a dividend.
What is the ChartMill rating of LEAP THERAPEUTICS INC stock?
LPTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the next earnings date for LPTX stock?
LEAP THERAPEUTICS INC (LPTX) will report earnings on 2026-03-24, after the market close.